HI
CARM

Harbour Investments’s Carisma Therapeutics CARM Stock Holding History

Harbour Investments’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37
Closed -$10 – 3886
2025
Q3 		$10 Hold
37
– – ﹤0.01% 3722
2025
Q2 		$14 Hold
37
– – ﹤0.01% 3582
2025
Q1 		$11 Hold
37
– – ﹤0.01% 3534
2024
Q4 		$15 Hold
37
– – ﹤0.01% 3463
2024
Q3 		$36 Hold
37
– – ﹤0.01% 3357
2024
Q2 		$56 Buy
+37
New +$55 ﹤0.01% 3234
2021
Q4 		– Sell
-1,000
Closed -$16K – 2768
2021
Q3 		$16K Buy
+1,000
New +$48K ﹤0.01% 2404

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

Harbour Investments's CARM Position: Q4 2025 in Review

Harbour Investments sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 37 shares — an estimated $10 sold.

Harbour Investments first reported a position in CARM in Q3 2021 and held it in 7 quarters. The position peaked at $16K in Q3 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • Harbour Investments reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Harbour Investments sold 37 Carisma Therapeutics shares in Q4 2025, an estimated $10.
  • Harbour Investments first reported a position in Carisma Therapeutics in Q3 2021 and held it in 7 quarters.
  • Harbour Investments's Carisma Therapeutics position peaked at $16K in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on Harbour Investments's 13F filing for Q4 2025, filed 9 Feb 2026.